Teleflex Inc Stock Price, News & Analysis

Teleflex has partnered with Explorer Surgical to enhance training for urologists using the UroLift® System. This collaboration introduces the Explorer Live digital platform, promoting remote learning and collaboration through an interactive digital playbook. Surgeons can access tailored surgical information, real-time education, and video capabilities during procedures. The UroLift System offers a minimally invasive solution for benign prostatic hyperplasia, improving patient outcomes and access to effective treatments.

Teleflex (NYSE: TFX) responded to the November 3, 2021, release of the CMS 2022 Medicare Physician Fee Schedule (MPFS) Final Rule, effective January 1, 2022. The rule reduces Non-Facility Practice Expense Relative Value Units, impacting reimbursement for over 600 procedures, including the UroLift System. CEO Liam Kelly expressed disappointment, noting potential patient migration to outpatient settings due to reimbursement changes. The UroLift CPT codes will see fee reductions of 8% and 11%, respectively, and a phased implementation over four years. Financial implications will be discussed in Q4 2021 results.

Teleflex (NYSE: TFX) announced that its UroLift® System won a Bronze Award for 'Best New Branded Television Campaign' and an Honorable Mention for 'Best Branded Website' at the DTC National Advertising Awards. The successful 25-week campaign highlighted lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) and resulted in a 146% increase in website traffic. This recognition showcases Teleflex's creativity in a competitive space dominated by larger pharmaceutical companies.

Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on December 15, 2021, to shareholders recorded by close of business on November 15, 2021. This move reflects the company's commitment to delivering value to its shareholders. Teleflex is a global provider of medical technologies, focusing on improving health and quality of life through innovative solutions in various medical fields. For more details, visit teleflex.com.

Teleflex reported strong financial results for Q3 2021, with revenues of $700.3 million, reflecting an 11.5% year-over-year increase. GAAP diluted EPS rose to $4.20, up from $2.46 a year prior, while adjusted diluted EPS reached $3.51, a 26.7% increase. Despite these positive results, the company lowered its revenue growth guidance due to COVID-19 impacts, now projecting 10-11% GAAP revenue growth and 8-9% constant currency growth. CEO Liam Kelly noted challenges, particularly for the UroLift product line, but emphasized the benefits of a diversified product portfolio.

Teleflex (NYSE: TFX) has completed patient enrollment in a clinical study assessing the QuikClot Control+® Hemostatic Device for mild to moderate bleeding during cardiac surgeries. The study, which aimed to measure hemostasis rates, enrolled 231 patients across seven sites, finishing three months ahead of schedule. Principal investigators express optimism about sharing findings related to various cardiac procedures. The QuikClot Control+® is FDA-cleared for severe bleeding but is investigational in this study, with plans for a 510(k) filing upon analysis completion.

Teleflex Incorporated (NYSE: TFX) will host a conference call to discuss its third quarter financial results on October 28, 2021, at 8:00 a.m. Eastern Time. Interested parties can register for the call via a provided link, which will also allow access to a live audio webcast on the company's website. An audio replay will be available following the call. Teleflex is a global provider of medical technologies, focusing on innovation to meet clinical needs and improve healthcare outcomes.

Teleflex announced new data at the American Urological Association meeting indicating that the UroLift System has the lowest rate of return procedures among treatments for benign prostatic hyperplasia (BPH). The study compared outcomes of UroLift with TURP, GreenLight, and Rezūm using data from U.S. Medicare and commercial claims from 2015 to 2019, which included over 35,000 patients. The findings highlight that while surgical retreatment rates are similar between UroLift, TURP, and GreenLight, Rezūm showed a significantly higher rate of surgical retreatment, positioning UroLift as a preferred option for BPH treatment.

On September 9, 2021, Teleflex announced the launch of two innovative products for the UroLift System: the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System. These products enhance treatment for benign prostatic hyperplasia (BPH) and will be showcased at the AUA Annual Meeting. The UroLift ATC features an improved delivery device for easier treatment, while the UroLift 2 System offers enhancements for user confidence. Data presented at the meeting will demonstrate the efficacy and safety of UroLift procedures, crucial for BPH management in men 45 and older.